FDMT vs PSA · rev $37.0K vs rev $4.82B
4D Molecular Therapeutics Inc (FDMT) versus PSA (PSA) — a side-by-side from cached financials, not a winner call.
4D Molecular Therapeutics Inc (FDMT) is a biotechnology company listed on US.
PSA (PSA) common stock.
Latest reported FDMT revenue for 2024-12-31 was $37.0K. Net income was -$160.9M. Revenue was down 99.8% from 2023-12-31 to 2024-12-31. FDMT currently screens at market cap $518.1M.
Latest reported PSA revenue for 2025-12-31 was $4.82B. Net income was $1.78B. Revenue was up 2.7% from 2024-12-31 to 2025-12-31. PSA currently screens at market cap $0.
FDMT currently screens at market cap $518.1M. PSA currently screens at market cap $0.
Not investment advice. Open the FDMT and PSA stock pages for the full models.
Not investment advice.